HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Southlake, TX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has included AI-ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval would allow outpatient settings to receive reimbursement for HeartSciences’ MyoVista® wavECG^TM algorithm and MyoVista® Insights^TM low ejection fraction algorithm, upon FDA clearance. The payment rate is expected to be $125.

Read more at globenewswire.com